Experience in the management of pediatric patients with Gaucher disease

Main Article Content

María Teresa Pompa-Garza
María Guadalupe González-Villarreal
José Luis Cedillo-de la Cerda

Keywords

Gaucher Disease, Lysosomal Storage Diseases, Beta-glucosidase,   Glucosylceramidase

Abstract

Among lysosomal storage diseases, Gaucher disease depicts the highest rate of incidence, according to the international epidemiological reports. Gaucher disease is due to an impairing of the acid beta-glucosidase enzyme, since its lack promotes accumulation of the sphingolipid glucosylceramide at macrophages, leading to heterogeneous multi-organic damage (visceral, skeletal, and central nervous system affectation). This paper portrays a series of clinical cases of Gaucher disease with patients treated at the same city (Monterrey, Nuevo León), at the Paediatric Haematology Department of the Hospital de Especialidades No. 25, in Monterrey of the Instituto Mexicano del Seguro Social. Gaucher disease is symptomatic since early childhood in a good proportion of patients. The patients in this serie was treated with enzyme replacement therapy, and share the typical overall features of the disease.

 

Abstract 41 | PDF (Spanish) Downloads 12

References

Franco-Ornelas S; Grupo de Expertos en Enfermedad de Gaucher. Consenso Mexicano de Enfermedad de Gaucher. Rev Med Inst Mex Seguro Soc. 2010; 48 (2):167-186.

 

Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol. 2005; 129 (2):178-188.

 

Charrow J, Anderson H, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr. 2004; 144 (1):112-205. 

 

Beck M. Therapy for lysosomal storage disorders. IUBMB Life. 2010; 62 (1):33-40. 

 

Cox TM. Recommendations for treating patients with Gaucher disease with emerging enzyme products. Blood Cell Mol Dis. 2010; 44 (2):84-85.